Blood cancer immunotherapy Sellas passes clinical trial

Adam Feuerstein is a senior biotechnology writer and columnist, reporting on the intersection of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotechnology podcast The Readout Loud and author of the Adam’s Biotech Scorecard newsletter. You can reach Adam on Signal at stataf.54.

It seems I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.

On Tuesday, Sellas said the treatment, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with advanced acute myeloid leukemia (AML) – a result that met the primary endpoint of a phase 3 clinical trial, the company said.

In a column published in September, I predicted that galinpepimut would fail to prolong survival in the phase 3 study.

Exclusive STAT+ story

STAT+

This article is reserved for STAT+ subscribers

Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.

Already have an account? Log in

See all packages

To read the rest of this story, subscribe to STAT+.

Subscribe

Gn bussni

Logo